{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:43:30Z","timestamp":1777484610905,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"National Key R&D Program of China, Ministry of Science and Technology of the People\u2019s Republic of China","award":["2022YFC2407100"],"award-info":[{"award-number":["2022YFC2407100"]}]},{"name":"National Key R&D Program of China, Ministry of Science and Technology of the People\u2019s Republic of China","award":["2022YFC2407102"],"award-info":[{"award-number":["2022YFC2407102"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study evaluates the clinical outcomes, survival benefits, and toxicities of two moderate-hypofractionated radiotherapy (MHRT) patterns, 60\u00a0Gy in 20 fractions (60\u00a0Gy\/20f) and 70\u00a0Gy in 28 fractions (70\u00a0Gy\/28f), in early-stage prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed data from 187 patients diagnosed between 2014 and 2023, using propensity score matching to ensure efficacy assessment accuracy. The primary endpoints reported were overall survival (OS) and disease-free survival (DFS), calculated using Kaplan-Meier analysis. Toxicity and side effects were evaluated using Criteria for Adverse Events v5.0, focusing on the urinary and gastrointestinal (GI) systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After matching, each of the 60\u00a0Gy and 70\u00a0Gy groups included 73 patients. The median follow-up duration for all patients was 36.0 months. The OS rates for the 60\u00a0Gy and 70\u00a0Gy groups were 86.3% and 89.0%, respectively, with 3-year OS rates of 92.4% and 89.0% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.375). The 3-year DFS rates were 91.0% in the 60\u00a0Gy group and 81.0% in the 70\u00a0Gy group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.096), indicating no significant differences between the groups. The incidence of acute Grade 2 or higher urinary toxicities was comparable between the two groups (60\u00a0Gy group vs 70\u00a0Gy group: 9.6% vs 9.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 1.0), while the 70\u00a0Gy group demonstrated an advantage for late Grade 2 or higher toxicities (60\u00a0Gy group vs 70\u00a0Gy group: 12.3% vs 2.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .028). For the GI system, the incidence of acute toxicities was higher in the 60\u00a0Gy group, albeit not statistically significant (60\u00a0Gy group vs 70\u00a0Gy group: 11.0% vs 6.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .383), while late toxicities were equivalent between the groups (60\u00a0Gy group vs 70\u00a0Gy group: 1.4% vs 1.4%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 1.0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both MHRT fractionation patterns demonstrate comparable survival outcomes and toxicities in early-stage prostate cancer, suggesting MHRT\u2019s viability as a primary treatment. The 60\u00a0Gy\/20f pattern marginally favored survival, albeit not with statistical significance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748251330058","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:15:29Z","timestamp":1744478129000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Moderate-Hypofractionated Radical Radiotherapy for Early-Stage Prostate Cancer: A Propensity Score Matching Analysis Comparing Dose Fractionation Patterns"],"prefix":"10.1177","volume":"32","author":[{"given":"Yinjie","family":"Tao","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weishi","family":"Cheng","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"},{"name":"Chinese Academy of Medical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongnan","family":"Zhen","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Guan","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Hou","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuquan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-2318","authenticated-orcid":false,"given":"Zhikai","family":"Liu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191"},{"key":"e_1_3_6_3_2","unstructured":"Prostate cancer statistics. World cancer research fund international. https:\/\/www.wcrf.org\/cancer-trends\/prostate-cancer-statistics\/. Accessed 4 May 2024."},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0019"},{"issue":"5","key":"e_1_3_6_5_2","first-page":"2523","article-title":"Comparison of physician-recorded toxicities and patient-reported outcomes of five different radiotherapy methods for","volume":"41","author":"Ito M","year":"2021","unstructured":"Ito M, Sasamura K, Takase Y, et al. Comparison of physician-recorded toxicities and patient-reported outcomes of five different radiotherapy methods for. Prostate Cancer. 2021;41(5):2523-2531.","journal-title":"Prostate Cancer"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2018.08.002"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/02841860410002824"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00438-6"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.075"},{"issue":"3","key":"e_1_3_6_10_2","first-page":"1009","article-title":"Is the \u03b1\/\u03b2 ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?","volume":"33","author":"Fowler JF","year":"2013","unstructured":"Fowler JF, Toma-Dasu I, Dasu A. Is the \u03b1\/\u03b2 ratio for prostate tumours really low and does it vary with the level of risk at diagnosis? Anticancer Res. 2013;33(3):1009-1011.","journal-title":"Anticancer Res"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2007.02.007"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12430"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01678-w"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31131-6"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13480"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.11.969"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.01.014"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.01.050"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.0448"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.07.021"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.1691"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1972"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70482-6"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30070-5"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7397"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9868"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6752"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.09.007"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.304"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.2340\/sju.v58.7719"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2007.10.012"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.07.027"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03282"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251330058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748251330058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748251330058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:23:34Z","timestamp":1777386214000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748251330058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":36,"alternative-id":["10.1177\/10732748251330058"],"URL":"https:\/\/doi.org\/10.1177\/10732748251330058","relation":{},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"article-number":"10732748251330058"}}